Browsing by Author Jianming Zhang

Jump to:
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 13 of 13

Issue DateTitleAuthor(s)
2010-03A Structure-Guided Approach to Creating Covalent FGFR InhibitorsWenjun Zhou; 허우영; Ultan McDermott, et al
2010-08A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl최환근; Pingda Ren; Francisco Adrian, et al
2010-07Broad spectrum alkynyl inhibitors of T315I Bcr-Abl임상민; Xianming Deng; Jianming Zhang, et al
2008-07Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase허우영; Anastasia Velentza; Sungjoon Kim, et al
2012-09Development of ATP-Competitive mTOR Inhibitors허우영; Qingsong Liu; Seong A. Kang, et al
2012-08Development of ‘DFG-out’ inhibitors of gatekeeper mutant kinases최환근; Jianming Zhang; Ellen Weisberg, et al
2010-09Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of CancerQingsong Liu; Jae Won Chang; Jinhua Wang, et al
2012-01Discovery of Potent and Selective Covalent Inhibitors of JNKTinghu Zhang; Francisco Inesta-Vaquera; Mario Niepel, et al
2015-01Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)Li Tan; Tyzoon Nomanbhoy; Deepak Gurbani, et al
2010-10Expanding the Diversity of Allosteric Bcr-Abl InhibitorsXianming Deng; Barun Okram; Qiang Ding, et al
2015-05Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approachAtsushi Nonami; Martin Sattler; Ellen Weisberg, et al
2012-04Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine KinaseSabine Hellwig; Chandra V. Miduturu; Shigeru Kanda, et al
2010-01Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang; Francisco J. Adrian; Wolfgang Jahnke, et al

BROWSE